title: In vitro controlled release of colon targeted mesalamine from compritol ATO 888 based matrix tablets using factorial design.
abstract: A controlled release matrix formulation for mesalamine was designed and developed to achieve a 24 h release profile. Using compritol 888 ATO (glyceryl behenate) as an inert matrix-forming agent to control the release of mesalamine, formulation granules containing the solid dispersions were investigated. Pectin, a polysaccharide, was used as bacterial dependent polymer for colon targeting. The matrix tablets for these formulations were prepared by direct compression and their in vitro release tests were carried out. A 3(2) full factorial design was used for optimization by taking the amounts of glyceryl behenate (X(1)) and pectin (X(2)) as independent variables and percentage drug released at 2 (Q(2)), 16 (Q(16)) and 24 (Q(24)) h as dependent variables. Drug release from the matrix tablets formulations lasted for over 24 h. Images of the tablet surface and cross-section were characterized by scanning electron microscopy to show the formed pores and channels in the matrices. These may provide the release pathway for the inner embedded drugs. The co-mixing of polysaccharide pectin, into the waxy matrices played a meaningful role in targeting the tablets to colon. The drug release from the novel formulation may be attributed to the diffusion-controlled mechanism. The results of the full factorial design indicated that an optimum amount of compritol ATO 888 and a high amount of pectin favors the colon targeting and controlled release of mesalamine from dosage form.
authors: Nootan Pharmacy College, Visnagar, Gujarat - 384 315, India.
authors: J K
authors: JK
authors: Patel
authors: N V
authors: NV
authors: Patel
authors: S H
authors: SH
authors: Shah
references: Int J Pharm. 2002 Jan 14;231(2):131-44
references: 11755266
references: Int J Pharm. 1999 Nov 5;189(2):179-85
references: 10536246
references: J Pharm Pharm Sci. 2004 Sep 24;7(3):325-31
references: 15576012
references: Int J Pharm. 2001 Aug 14;224(1-2):19-38
references: 11472812
references: J Control Release. 1998 Feb 12;51(2-3):281-7
references: 9685926
references: J Pharm Sci. 2001 Nov;90(11):1767-75
references: 11745734
references: J Pharm Sci. 1983 Oct;72(10):1189-91
references: 6644570
references: Int J Pharm. 2003 Mar 26;254(2):281-6
references: 12623204
references: Int J Pharm. 2002 Mar 20;235(1-2):1-15
references: 11879735
references: Int J Pharm. 2002 Apr 2;236(1-2):111-23
references: 11891075
references: Chem Pharm Bull (Tokyo). 2004 Aug;52(8):972-3
references: 15304992
references: Adv Drug Deliv Rev. 2001 Jun 11;48(2-3):139-57
references: 11369079
references: Eur J Pharm Biopharm. 1999 Jan;47(1):87-90
references: 10234531
references: Eur J Pharm Sci. 2003 Jan;18(1):3-18
references: 12554067
references: J Pharm Sci. 1993 Jul;82(7):750-4
references: 8360851
references: AAPS PharmSciTech. 2003 Dec 12;4(4):E61
references: 15198556
references: Int J Pharm. 2002 Apr 2;236(1-2):43-55
references: 11891069
references: Pharmazie. 2001 Sep;56(9):718-23
references: 11593992
references: Int J Pharm. 2003 Jan 30;251(1-2):79-84
references: 12527177
references: J Drug Target. 1998;6(2):129-49
references: 9886237
references: J Pharm Sci. 1963 Dec;52:1145-9
references: 14088963
references: J Pharm Pharmacol. 1995 Mar;47(3):182-7
references: 7602477